USA - NYSE:HAE - US4050241003 - Common Stock
ChartMill assigns a Buy % Consensus number of 81% to HAE. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-21 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-10-07 | Citigroup | Maintains | Buy -> Buy |
| 2025-09-23 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-08-11 | Raymond James | Downgrade | Strong Buy -> Outperform |
| 2025-08-08 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-08-08 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-08-08 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2025-08-07 | Needham | Maintains | Buy -> Buy |
| 2025-07-11 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-07-09 | Citigroup | Upgrade | Neutral -> Buy |
| 2025-06-26 | Baird | Initiate | Outperform |
| 2025-05-20 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2025-05-09 | Raymond James | Reiterate | Strong Buy -> Strong Buy |
| 2025-05-08 | Needham | Maintains | Buy -> Buy |
| 2025-03-18 | Needham | Maintains | Buy -> Buy |
| 2025-02-07 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-02-07 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-02-07 | Needham | Maintains | Buy -> Buy |
| 2025-02-07 | Raymond James | Reiterate | Strong Buy -> Strong Buy |
| 2024-12-06 | JP Morgan | Initiate | Overweight |
| 2024-12-04 | Barrington Research | Maintains | Outperform -> Outperform |
| 2024-12-03 | Needham | Reiterate | Buy -> Buy |
| 2024-11-15 | Needham | Reiterate | Buy -> Buy |
| 2024-11-08 | Barrington Research | Maintains | Outperform -> Outperform |
| 2024-11-08 | Raymond James | Upgrade | Outperform -> Strong Buy |
| 2024-09-23 | Barrington Research | Maintains | Outperform -> Outperform |
| 2024-09-13 | CL King | Initiate | Buy |
| 2024-09-11 | B of A Securities | Initiate | Neutral |
| 2024-09-10 | BTIG | Initiate | Buy |
| 2024-08-22 | Citigroup | Maintains | Neutral -> Neutral |
15 analysts have analysed HAE and the average price target is 81.91 USD. This implies a price increase of 63.78% is expected in the next year compared to the current price of 50.01.
The consensus rating for HAEMONETICS CORP/MASS (HAE) is 81.3333 / 100 . This indicates that analysts generally have a positive outlook on the stock.